A condition characterized by poorly-circumscribed gelatinous masses filled with malignant mucin-secreting cells. Forty-five percent of pseudomyxomas arise from the ovary, usually in a mucinous cystadenocarcinoma (CYSTADENOCARCINOMA, MUCINOUS), which has prognostic significance. Pseudomyxoma peritonei must be differentiated from mucinous spillage into the peritoneum by a benign mucocele of the appendix. (Segen, Dictionary of Modern Medicine, 1992)
Tumors or cancer of the PERITONEUM.
Tumors or cancer of the APPENDIX.
A retention cyst of the salivary gland, lacrimal sac, paranasal sinuses, appendix, or gallbladder. (Stedman, 26th ed)
A worm-like blind tube extension from the CECUM.
A gel-forming mucin found predominantly in SMALL INTESTINE and variety of mucous membrane-containing organs. It provides a protective, lubricating barrier against particles and infectious agents.
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.
Abnormally high temperature intentionally induced in living things regionally or whole body. It is most often induced by radiation (heat waves, infra-red), ultrasound, or drugs.
A gel-forming mucin that is primarily found on the surface of gastric epithelium and in the RESPIRATORY TRACT. Mucin 5AC was originally identified as two distinct proteins, however a single gene encodes the protein which gives rise to the mucin 5A and mucin 5C variants.
Neoplasm drug therapy involving an extracorporeal circuit with temporary exclusion of the tumor-bearing area from the general circulation during which high concentrations of the drug are perfused to the isolated part.
High molecular weight mucoproteins that protect the surface of EPITHELIAL CELLS by providing a barrier to particulate matter and microorganisms. Membrane-anchored mucins may have additional roles concerned with protein interactions at the cell surface.
Surgical removal of the vermiform appendix. (Dorland, 28th ed)
An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
A membrane of squamous EPITHELIAL CELLS, the mesothelial cells, covered by apical MICROVILLI that allow rapid absorption of fluid and particles in the PERITONEAL CAVITY. The peritoneum is divided into parietal and visceral components. The parietal peritoneum covers the inside of the ABDOMINAL WALL. The visceral peritoneum covers the intraperitoneal organs. The double-layered peritoneum forms the MESENTERY that suspends these organs from the abdominal wall.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.

Molecular genetic evidence supporting the clonality and appendiceal origin of Pseudomyxoma peritonei in women. (1/75)

Pseudomyxoma peritonei (PMP) is a poorly understood condition characterized by mucinous ascites and multifocal peritoneal mucinous tumors. Women with PMP often have mucinous tumors involving both the appendix and the ovaries. Several previous histopathological and immunohistochemical studies of PMP have suggested that most, if not all, cases of PMP in women are derived from mucinous adenomas of the appendix rather than from primary ovarian tumors. A few studies of the molecular genetics of PMP have been recently reported. However, these studies analyzed only a small number of cases and some included a heterogeneous group of mucinous tumors, including both benign and malignant appendiceal and ovarian tumors. We analyzed K-ras mutations and allelic losses of chromosomes 18q, 17p, 5q, and 6q in a substantial number of morphologically uniform cases of PMP with synchronous ovarian and appendiceal tumors as well as in appendiceal mucinous adenomas (MAs) and ovarian mucinous tumors of low malignant potential (MLMPs) unassociated with PMP. Each of the 16 PMP cases (100%) analyzed demonstrated identical K-ras mutations in the appendiceal adenoma and corresponding synchronous ovarian tumor. K-ras mutations were identified in 11 of 16 (69%) appendiceal MAs unassociated with PMP and in 12 of 16 (75%) ovarian MLMPs unassociated with PMP. Two PMP cases showed identical allelic losses in the matched ovarian and appendiceal tumors. A discordant pattern of allelic loss between the ovarian and appendiceal tumors at one or two of the loci tested was observed in six PMP cases. In all but one instance, LOH was observed in the ovarian tumor, whereas both alleles were retained in the matched appendiceal lesion, suggesting tumor progression in a secondary (metastatic) site. Our findings strongly support the conclusion that mucinous tumors involving the appendix and ovaries in women with PMP are clonal and derived from a single site, most likely the appendix.  (+info)

Pseudomyxoma peritoneii. (2/75)

A middle aged male patient presented with gradual distension of the abdomen. Imaging modalities showed classical features of pseudomyxoma peritoneii which was confirmed by aspiration cytology. Details of the case are described and relevant literature is reviewed.  (+info)

The coexistence of low-grade mucinous neoplasms of the appendix and appendiceal diverticula: a possible role in the pathogenesis of pseudomyxoma peritonei. (3/75)

We examined 38 appendectomies with diagnoses of mucocele, diverticulum, or adenoma to study the coincidence of appendiceal diverticula and appendiceal low-grade mucinous neoplasms and to examine the possible role of diverticula in the pathogenesis of pseudomyxoma peritonei. Invasive adenocarcinomas and retention cysts were excluded (six cases). Cases were classified as adenomas or mucinous tumors of unknown malignant potential, with or without diverticula. Medical records were reviewed for multiple parameters, including presenting symptoms, presence of pseudomyxoma peritonei, and presence of associated malignancies. Binomial statistics were used to calculate the probability that the observed prevalence of low-grade mucinous neoplasms and diverticula together was significantly different from the expected prevalence of diverticula or low-grade mucinous neoplasms alone, using historical controls from the literature. Twenty-five percent of the total cases (8 of 32) contained both a low-grade mucinous neoplasm (7 cystadenomas and 1 mucinous tumor of unknown malignant potential) and a diverticulum. Thus, 8 of 19 low-grade mucinous neoplasms (42%) were associated with diverticula. Of the appendices with both low-grade mucinous neoplasms and diverticula, three contained dissecting acellular mucin within the appendiceal wall, four showed diverticular perforation, and one had pseudomyxoma peritonei associated with the ruptured diverticulum. A significant percentage (P < .001) of cases contained low-grade mucinous neoplasms and diverticula together. The case of coexistent low-grade mucinous neoplasm, diverticulum, and pseudomyxoma peritonei suggests that diverticula could play a role in the pathogenesis of pseudomyxoma peritonei. This could occur either by involvement of preexisting diverticula by the neoplasm or by distention of the appendiceal lumen by mucin, leading to increased intraluminal pressure and subsequent diverticulum formation at a weak area in the wall. Either mechanism might allow low-grade mucinous neoplasms to penetrate the appendiceal wall more easily.  (+info)

Mucocele of the appendix secondary to endometriosis. Report of two cases, one with localized pseudomyxoma peritonei. (4/75)

This report documents 2 cases of obstructive mucocele of the appendix secondary to endometriosis of the appendix. In 1 case, the tip of the mucocele was ruptured and associated with localized pseudomyxoma peritonei. Mucoceles of the appendix usually are associated with hyperplastic or neoplastic mucosal proliferation; obstruction, particularly that due to endometriosis, is an infrequent cause. Occurrence of localized pseudomyxoma peritonei associated with appendiceal endometriosis and mucocele has not been reported previously.  (+info)

Recent advances in immunohistochemistry in the diagnosis of ovarian neoplasms. (5/75)

This leader reviews recent advances in immunohistochemistry that are useful in the diagnosis of ovarian neoplasms. These include the value of different anticytokeratin antibodies in the distinction between a primary ovarian adenocarcinoma and a metastatic adenocarcinoma, especially of colorectal origin. These antibodies have also helped to clarify the origin of the peritoneal disease in most cases of pseudomyxoma peritonei. The value of antibodies against so called tumour specific antigens, such as CA125 and HAM56, in determining the ovarian origin of an adenocarcinoma is also reviewed. In recent years, several studies have investigated the value of a variety of monoclonal antibodies in the diagnosis of ovarian sex cord stromal tumours and in the distinction between these neoplasms and their histological mimics. These antibodies include those directed against inhibin, CD99, Mullerian inhibiting substance, relaxin like factor, melan A, and calretinin. Of these, anti-alpha inhibin appears to be of most diagnostic value. It is stressed that these antibodies should always be used as part of a larger panel and not in isolation.  (+info)

Histopathologic analysis in 46 patients with pseudomyxoma peritonei syndrome: failure versus success with a second-look operation. (6/75)

Pseudomyxoma peritonei syndrome is a disease characterized by mucinous ascites and mucinous tumor disseminated on peritoneal surfaces; the disease almost always originates from a perforated appendiceal epithelial tumor. Histopathologic assessment of aggressive versus noninvasive character of the mucinous tumor has been shown to have an impact on survival in patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Out of a database of 312 patients having a complete cytoreduction for pseudomyxoma peritonei syndrome, 46 patients (24 male and 22 female) had at least one second-look surgery. Before this review, all 46 of these patients were clinically uniformly categorized with a diagnosis of pseudomyxoma peritonei. Using the criteria described by Ronnett and colleagues, all specimens from the multiple surgical procedures performed on these patients were reviewed and reclassified as disseminated peritoneal adenomucinosis (adenomucinosis), adenomucinosis/mucinous adenocarcinoma (hybrid), or mucinous adenocarcinoma. The review was performed in a blinded fashion by a single pathologist (HY). To facilitate a critical evaluation of these histopathologic assessments, the patients were separated into two groups: (1) 19 patients who had a second-look surgery that was unsuccessful in that they went on to die of their disease or in that they currently have disease progression and a limited survival and (2) 27 patients who had a successful second look and currently continue disease free with a minimum 3-year follow-up period. As a result of this review, 11 of 19 patients with an unsuccessful second look and originally designated pseudomyxoma peritonei were reclassified as hybrid-type malignancy (four patients) or mucinous adenocarcinoma (seven patients). Only two patients were reclassified in the successful second-look group (P =.0005). Transitions from a less aggressive to a more invasive histology from one cytoreduction to the next occurred on 13 occasions in patients whose second-look surgery failed and in one patient with a successful second-look surgery (P <.0001). Seven patients retained a histologic classification of disseminated peritoneal adenomucinosis but went on to die of an aggressive disease process. Clinical assessments suggested that failure of second-look surgery for pseudomyxoma peritonei was associated with a biologically more aggressive disease. Unsuccessful second-look surgery for patients with a clinical diagnosis of pseudomyxoma peritonei tumor was often related to an inaccurate initial histologic classification of appendiceal mucinous tumor. Also, a transition from less to more aggressive histology was frequently seen in patients dying of this disease. Assessment of tumor histology can predict the outcome if a uniform surgical treatment is used in patients with peritoneal dissemination of mucinous epithelial tumors of the appendix.  (+info)

Gelatinous ascites: a cytohistologic study of pseudomyxoma peritonei in 67 patients. (7/75)

BACKGROUND: Pseudomyxoma peritonei (PMP) is a rare condition characterized by gelatinous ascites. Although the histologic attributes of PMP have been well studied, the cytologic features remain ill defined. METHODS: We reviewed the peritoneal washings (PW) in 67 patients with PMP to identify cytomorphologic features useful in classifying cases as either disseminated peritoneal adenomucinosis (DPAM) or peritoneal mucinous carcinomatosis (PMCA). Histologic specimens were correlated with the cytologic diagnoses. Correlation between cytologic diagnosis and patient outcome was investigated. RESULTS: Neoplastic epithelial cells were identified in 63 of 67 PW (94%). Concordance with the histologic diagnosis was obtained in 61 of 63 cases. Of these 36.5% were cytologically classified as DPAM with primary appendiceal neoplasms in 19 cases. Thirty-four of 63 cases (53.9%) were cytologically diagnosed as PMCA based on PW cytology. Most were of appendiceal or colonic origin. Four cases displayed cytologic features of both DPAM and PMCA. Two discordant cases each with a cytologic diagnosis of PMCA had an appendiceal adenoma. Acellular mucin alone was identified in the PW in four cases. Analysis of follow-up data revealed that cases diagnosed as DPAM had a better prognosis than those diagnosed as PMCA. CONCLUSIONS: Cytomorphologic features of epithelial cells in PW material can accurately categorize cases of PMP as either DPAM or PMCA. Furthermore, this categorization appears to have important prognostic implications.  (+info)

Pseudomyxoma peritonei of hernial sac--a case report. (8/75)

A rare presentation of Pseudomyxoma Peritonei of hernial sac is described. The patient was admitted for repair of an inguinal hernia. During herniorraphy large amount of mucinous material was found in hernial sac. Microscopy revealed epithelial glandular cells with bland appearance within mucinous pools. A search for primary remained fruitless.  (+info)

Pseudomyxoma Peritonei (PMP) is a rare, slow-growing, and invasive cancer that typically starts in the appendix as a low-grade mucinous neoplasm, although it can also arise from other organs of the abdominal cavity. The primary characteristic of PMP is the accumulation of copious amounts of gelatinous ascites (peritoneal fluid containing mucin) within the peritoneal cavity, causing progressive abdominal distension and discomfort.

The condition is classified into three main histological subtypes: disseminated peritoneal adenomucinosis (DPAM), peritoneal mucinous carcinomatosis (PMCA), and hybrid tumors. DPAM is the least aggressive form, while PMCA is more invasive and has a worse prognosis.

The primary treatment for Pseudomyxoma Peritonei involves cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC). This approach aims to remove all visible tumors and destroy any remaining cancer cells within the abdominal cavity. Early diagnosis and aggressive treatment can significantly improve the prognosis for patients with PMP, although long-term survival rates remain variable due to the disease's rarity and heterogeneity.

Peritoneal neoplasms refer to tumors or cancerous growths that develop in the peritoneum, which is the thin, transparent membrane that lines the inner wall of the abdomen and covers the organs within it. These neoplasms can be benign (non-cancerous) or malignant (cancerous). Malignant peritoneal neoplasms are often associated with advanced stages of gastrointestinal, ovarian, or uterine cancers and can spread (metastasize) to other parts of the abdomen.

Peritoneal neoplasms can cause various symptoms such as abdominal pain, bloating, nausea, vomiting, loss of appetite, and weight loss. Diagnosis typically involves imaging tests like CT scans or MRIs, followed by a biopsy to confirm the presence of cancerous cells. Treatment options may include surgery, chemotherapy, radiation therapy, or a combination of these approaches, depending on the type, stage, and location of the neoplasm.

Appendiceal neoplasms refer to various types of tumors that can develop in the appendix, a small tube-like structure attached to the large intestine. These neoplasms can be benign or malignant and can include:

1. Adenomas: These are benign tumors that arise from the glandular cells lining the appendix. They are usually slow-growing and may not cause any symptoms.
2. Carcinoids: These are neuroendocrine tumors that arise from the hormone-producing cells in the appendix. They are typically small and slow-growing, but some can be aggressive and spread to other parts of the body.
3. Mucinous neoplasms: These are tumors that produce mucin, a slippery substance that can cause the appendix to become distended and filled with mucus. They can be low-grade (less aggressive) or high-grade (more aggressive) and may spread to other parts of the abdomen.
4. Adenocarcinomas: These are malignant tumors that arise from the glandular cells lining the appendix. They are relatively rare but can be aggressive and spread to other parts of the body.
5. Pseudomyxoma peritonei: This is a condition in which mucin produced by an appendiceal neoplasm leaks into the abdominal cavity, causing a jelly-like accumulation of fluid and tissue. It can be caused by both benign and malignant tumors.

Treatment for appendiceal neoplasms depends on the type and stage of the tumor, as well as the patient's overall health. Treatment options may include surgery, chemotherapy, or radiation therapy.

A mucocele is a mucus-containing cystic lesion that results from the accumulation of mucin within a damaged minor salivary gland duct or mucous gland. It is typically caused by trauma, injury, or blockage of the duct. Mucocele appears as a round, dome-shaped, fluid-filled swelling, which may be bluish or clear in color. They are most commonly found on the lower lip but can also occur on other areas of the oral cavity. Mucocele is generally painless unless it becomes secondarily infected; however, it can cause discomfort during speaking, chewing, or swallowing, and may affect aesthetics. Treatment usually involves surgical excision of the mucocele to prevent recurrence.

The appendix is a small, tube-like structure that projects from the large intestine, located in the lower right quadrant of the abdomen. Its function in humans is not well understood and is often considered vestigial, meaning it no longer serves a necessary purpose. However, in some animals, the appendix plays a role in the immune system. Inflammation of the appendix, known as appendicitis, can cause severe abdominal pain and requires medical attention, often leading to surgical removal of the appendix (appendectomy).

Mucin-2, also known as MUC2, is a type of mucin that is primarily produced by the goblet cells in the mucous membranes lining the gastrointestinal tract. It is a large, heavily glycosylated protein that forms the gel-like structure of mucus, which provides lubrication and protection to the epithelial surfaces. Mucin-2 is the major component of intestinal mucus and plays an important role in maintaining the integrity of the gut barrier by preventing the adhesion and colonization of harmful microorganisms. Additionally, it has been shown to have anti-inflammatory properties and may play a role in regulating immune responses in the gut.

Adenocarcinoma, mucinous is a type of cancer that begins in the glandular cells that line certain organs and produce mucin, a substance that lubricates and protects tissues. This type of cancer is characterized by the presence of abundant pools of mucin within the tumor. It typically develops in organs such as the colon, rectum, lungs, pancreas, and ovaries.

Mucinous adenocarcinomas tend to have a distinct appearance under the microscope, with large pools of mucin pushing aside the cancer cells. They may also have a different clinical behavior compared to other types of adenocarcinomas, such as being more aggressive or having a worse prognosis in some cases.

It is important to note that while a diagnosis of adenocarcinoma, mucinous can be serious, the prognosis and treatment options may vary depending on several factors, including the location of the cancer, the stage at which it was diagnosed, and the individual's overall health.

Mucinous cystadenoma is a type of benign tumor that arises from the epithelial cells lining the mucous membranes of the body. It is most commonly found in the ovary, but can also occur in other locations such as the pancreas or appendix.

Mucinous cystadenomas are characterized by the production of large amounts of mucin, a slippery, gel-like substance that accumulates inside the tumor and causes it to grow into a cystic mass. These tumors can vary in size, ranging from a few centimeters to over 20 centimeters in diameter.

While mucinous cystadenomas are generally benign, they have the potential to become cancerous (mucinous cystadenocarcinoma) if left untreated. Symptoms of mucinous cystadenoma may include abdominal pain or swelling, bloating, and changes in bowel movements or urinary habits. Treatment typically involves surgical removal of the tumor.

Hyperthermia, induced, is a medically controlled increase in core body temperature beyond the normal range (36.5-37.5°C or 97.7-99.5°F) to a target temperature typically between 38-42°C (100.4-107.6°F). This therapeutic intervention is used in various medical fields, including oncology and critical care medicine. Induced hyperthermia can be achieved through different methods such as whole-body heating or localized heat application, often combined with chemotherapy or radiation therapy to enhance treatment efficacy.

In the context of oncology, hyperthermia is used as a sensitizer for cancer treatments by increasing blood flow to tumors, enhancing drug delivery, and directly damaging cancer cells through protein denaturation and apoptosis at higher temperatures. In critical care settings, induced hyperthermia may be applied in therapeutic hypothermia protocols to protect the brain after cardiac arrest or other neurological injuries by decreasing metabolic demand and reducing oxidative stress.

It is essential to closely monitor patients undergoing induced hyperthermia for potential adverse effects, including cardiovascular instability, electrolyte imbalances, and infections, and manage these complications promptly to ensure patient safety during the procedure.

Mucin 5AC, also known as MUC5AC, is a type of mucin protein that is heavily glycosylated and secreted by the goblet cells in the mucous membranes of the respiratory and gastrointestinal tracts. It plays an essential role in the protection and lubrication of these surfaces, as well as in the clearance of inhaled particles and microorganisms from the lungs.

MUC5AC is a high molecular weight mucin that forms a gel-like substance when secreted, which traps foreign particles and pathogens, facilitating their removal from the body. Abnormalities in MUC5AC production or function have been implicated in various respiratory and gastrointestinal diseases, including chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis, and inflammatory bowel disease (IBD).

In summary, Mucin 5AC is a crucial component of the mucosal defense system in the respiratory and gastrointestinal tracts, contributing to the maintenance of tissue homeostasis and protection against infection and injury.

Regional perfusion chemotherapy for cancer is a medical treatment in which a specific area or region of the body is infused with high concentrations of cancer-killing (cytotoxic) drugs via a temporary isolation and perfusion of that region. This technique is typically used to treat isolated areas of cancer that are locally advanced, recurrent, or cannot be removed surgically.

The procedure involves isolating the regional blood circulation by cannulating the artery and vein that supply blood to the target area, often the limbs (such as in melanoma or sarcoma) or the liver (for liver tumors). The chemotherapeutic drugs are then introduced into the isolated arterial circulation, allowing for a high concentration of the drug to be delivered directly to the cancerous tissue while minimizing systemic exposure and toxicity.

After the infusion, the region is rinsed with a blood-substitute solution to remove any residual chemotherapeutic agents before reconnecting the circulation. This procedure can be repeated multiple times if necessary.

Regional perfusion chemotherapy has been shown to improve local control and potentially increase survival rates in certain types of cancer, while reducing systemic side effects compared to traditional intravenous chemotherapy. However, it is a complex and invasive procedure that requires specialized medical expertise and facilities.

Mucins are high molecular weight, heavily glycosylated proteins that are the major components of mucus. They are produced and secreted by specialized epithelial cells in various organs, including the respiratory, gastrointestinal, and urogenital tracts, as well as the eyes and ears.

Mucins have a characteristic structure consisting of a protein backbone with numerous attached oligosaccharide side chains, which give them their gel-forming properties and provide a protective barrier against pathogens, environmental insults, and digestive enzymes. They also play important roles in lubrication, hydration, and cell signaling.

Mucins can be classified into two main groups based on their structure and function: secreted mucins and membrane-bound mucins. Secreted mucins are released from cells and form a physical barrier on the surface of mucosal tissues, while membrane-bound mucins are integrated into the cell membrane and participate in cell adhesion and signaling processes.

Abnormalities in mucin production or function have been implicated in various diseases, including chronic inflammation, cancer, and cystic fibrosis.

An appendectomy is a surgical procedure in which the vermiform appendix is removed. This procedure is performed when a patient has appendicitis, which is an inflammation of the appendix that can lead to serious complications such as peritonitis or sepsis if not treated promptly. The surgery can be done as an open procedure, in which a single incision is made in the lower right abdomen, or as a laparoscopic procedure, in which several small incisions are made and specialized instruments are used to remove the appendix. In some cases, if the appendix has burst, a more extensive surgery may be required to clean out the abdominal cavity.

Mitomycin is an antineoplastic antibiotic derived from Streptomyces caespitosus. It is primarily used in cancer chemotherapy, particularly in the treatment of various carcinomas including gastrointestinal tract malignancies and breast cancer. Mitomycin works by forming cross-links in DNA, thereby inhibiting its replication and transcription, which ultimately leads to cell death.

In addition to its systemic use, mitomycin is also used topically in ophthalmology for the treatment of certain eye conditions such as glaucoma and various ocular surface disorders. The topical application of mitomycin can help reduce scarring and fibrosis by inhibiting the proliferation of fibroblasts.

It's important to note that mitomycin has a narrow therapeutic index, meaning there is only a small range between an effective dose and a toxic one. Therefore, its use should be closely monitored to minimize side effects, which can include myelosuppression, mucositis, alopecia, and potential secondary malignancies.

The peritoneum is the serous membrane that lines the abdominal cavity and covers the abdominal organs. It is composed of a mesothelial cell monolayer supported by a thin, loose connective tissue. The peritoneum has two layers: the parietal peritoneum, which lines the abdominal wall, and the visceral peritoneum, which covers the organs.

The potential space between these two layers is called the peritoneal cavity, which contains a small amount of serous fluid that allows for the smooth movement of the organs within the cavity. The peritoneum plays an important role in the absorption and secretion of fluids and electrolytes, as well as providing a surface for the circulation of immune cells.

In addition, it also provides a route for the spread of infection or malignant cells throughout the abdominal cavity, known as peritonitis. The peritoneum is highly vascularized and innervated, making it sensitive to pain and distention.

Multiple primary neoplasms refer to the occurrence of more than one primary malignant tumor in an individual, where each tumor is unrelated to the other and originates from separate cells or organs. This differs from metastatic cancer, where a single malignancy spreads to multiple sites in the body. Multiple primary neoplasms can be synchronous (occurring at the same time) or metachronous (occurring at different times). The risk of developing multiple primary neoplasms increases with age and is associated with certain genetic predispositions, environmental factors, and lifestyle choices such as smoking and alcohol consumption.

... is a global charity (non-profit) which supports and advises patients with pseudomyxoma peritonei. It is ... "Pseudomyxoma peritonei". "Sean Hepburn Ferrer, Patron of Pseudomyxoma Survivor". "Rare Disease Day 2017 - 28 Feb - Article". ... The patron of the charity is Sean Hepburn-Ferrer, the son of Audrey Hepburn who died of pseudomyxoma peritonei in 1993. Sean ... The charity is listed by Macmillan Cancer Support as the primary support route for pseudomyxoma peritonei and is also ...
Its main complication is pseudomyxoma peritonei. Gross pathology of mucocele of the appendix Pie chart of histological types of ...
Some examples would include: Pseudomyxoma peritonei: A build-up of mucus in the peritoneal cavity. The mucus may come from ... as well as certain sarcomas and pseudomyxoma peritonei. Treatment options for such advanced diseases are limited to systemic ...
... originate from appendix cancer spillage and pseudomyxoma peritonei. Unknown primary tumors and rarely, urinary or respiratory ...
Fluid can be serous as seen in primary peritoneal carcinoma or mucinous such as found in pseudomyxoma peritonei which is ... Young, Robert H. (2004). "Pseudomyxoma peritonei and selected other aspects of the spread of appendiceal neoplasms". Seminars ...
One rare but noteworthy condition associated with mucinous ovarian neoplasms is pseudomyxoma peritonei. As primary ovarian ... see mucinous adenocarcinoma with clinical condition Pseudomyxoma peritonei). Clear stromal invasion is used to differentiate ...
He died from pseudomyxoma peritonei, a rare form of appendix cancer, while in office. He is buried at the Wilder Cemetery. ...
Pseudomyxoma peritonei may present as a result of an ovarian mucinous tumor, however this is a rare cause of this condition, ... A more common cause of pseudomyxoma peritonei is a mucin-producing tumor of the appendix. Since mucinous tumors arising from ...
Microcystic adnexal carcinoma Primary cutaneous adenoid cystic carcinoma List of cutaneous conditions Pseudomyxoma peritonei ...
In 2000 Bandy developed pseudomyxoma peritonei, a form of cancer that caused tumors to form in his abdomen. He underwent ...
... complications from pseudomyxoma peritonei. Rodney Cass, 78, English cricketer (Essex, Tasmania, Worcestershire). Jeremy Catto, ...
... a mixed histology as well as the presence of pseudomyxoma peritonei must be ruled out. These are considered a differentiated ...
Boswell died in Des Moines, Iowa on August 17, 2018, after suffering from complications of pseudomyxoma peritonei, a rare form ...
In September 2006, Prescott was diagnosed with pseudomyxoma peritonei, a rare form of cancer, and was told that he would not ...
Pseudomyxoma peritonei refers to a collection of encapsulated mucous or gelatinous material in the abdominopelvic cavity, which ...
Common disease presentations that are different but may appear similar include pseudomyxoma peritonei, peritoneal mesothelioma ...
... pseudomyxoma peritonei MeSH C04.557.470.615 - neoplasms, ductal, lobular, and medullary MeSH C04.557.470.615.132 - carcinoma, ...
Examples of tumors include Primary peritoneal carcinoma Pseudomyxoma peritonei Examples of sarcomas include: Soft-tissue ...
... a type of plastic Prescription monitoring program Pseudomyxoma peritonei, a cancer Denel PMP, company division Project ...
M8480/6 Pseudomyxoma peritonei M8481/3 Mucin-producing adenocarcinoma Mucin-producing carcinoma Mucin-secreting adenocarcinoma ... Gelatinous carcinoma Mucoid adenocarcinoma Mucoid carcinoma Mucous adenocarcinoma Mucous carcinoma Pseudomyxoma peritonei with ...
... pseudomyxoma peritonei, and Sean Ferrer became the rare disease ambassador since 2014 and for 2015 on behalf of European ... in early November revealed a rare form of abdominal cancer belonging to a group of cancers known as pseudomyxoma peritonei. ... "Sean Hepburn Ferrer". Pseudomyxoma Survivor. Retrieved 5 July 2015. "Rare Disease Day ® 2015 - Sean Hepburn Ferrer, special ... Dotti also became patron of the Pseudomyxoma Survivor charity, dedicated to providing support to patients of the rare cancer ...
... pseudomyxoma peritonei - psoralen - PTC - PTCD - PTK787/ZK 222584 - ptosis - pulmonary sulcus tumor - PV701 - pyrazine ...
... aeruginosa infection Pseudomonas oryzihabitans infection Pseudomonas stutzeri infection Pseudomongolism Pseudomyxoma peritonei ...
Evidence-based recommendations on complete cytoreduction for pseudomyxoma peritonei (Sugarbaker technique). This involves ... Complete cytoreduction for pseudomyxoma peritonei (Sugarbaker technique). Interventional procedures guidance [IPG56]. Published ... Evidence-based recommendations on complete cytoreduction for pseudomyxoma peritonei (Sugarbaker technique). This involves ...
Pseudomyxoma peritonei, a rare disease, is characterized by accumulation of mucinous material in the peritoneal cavity and is ... Successful treatment of pseudomyxoma peritonei of ovarian origin with cis-platinum, doxorubicin, and cyclophosphamide ... Pseudomyxoma peritonei: Report of an Unusual Case. Oncology (1975) 32 (1): 21-26. ... A rare case of pseudomyxoma peritonei presenting an unusual inguinal hernia and splenic metastasis ...
Return to Article Details Pseudomyxoma peritonei presenting with port site hernia Download Download PDF ...
PubMed - Pseudomyxoma Peritonei (PMP) (79 unread) * Low-Grade Pseudomyxoma Peritonei Behaving as a High-Grade Disease: A Case ... Pseudomyxoma peritonei (PMP) remains difficult to diagnose and has a reserved prognosis. Pseudomyxoma peritonei is a rare ... CONCLUSION: Pseudomyxoma pleurii is a rare entity with a poor prognosis that usually arises secondary to Pseudomyxoma peritonei ... INTRODUCTION: Pseudomyxoma pleurii is a rare disease that is defined by the pleural extension of pseudomyxoma peritonei, ...
Pseudomyxoma Peritonei: A Case Report of an Incidental Finding at Cesarean Section ...
Pseudomyxoma Survivor is a global charity (non-profit) which supports and advises patients with pseudomyxoma peritonei. It is ... "Pseudomyxoma peritonei". "Sean Hepburn Ferrer, Patron of Pseudomyxoma Survivor". "Rare Disease Day 2017 - 28 Feb - Article". ... The patron of the charity is Sean Hepburn-Ferrer, the son of Audrey Hepburn who died of pseudomyxoma peritonei in 1993. Sean ... The charity is listed by Macmillan Cancer Support as the primary support route for pseudomyxoma peritonei and is also ...
Pseudomyxoma peritonei (PMP) is a rare and intractable disease with an estimated incidence of one per million population per ... Pseudomyxoma peritonei as an intractable disease and its preoperative assessment to help improve prognosis after surgery: A ...
CYTOREDUCTION AND MODIFIED MULTIVISCERAL TRANSPLANTATION FOR PATIENTS WITH END-STAGE PSEUDOMYXOMA PERITONEI ... CYTOREDUCTION AND MODIFIED MULTIVISCERAL TRANSPLANTATION FOR PATIENTS WITH END-STAGE PSEUDOMYXOMA PERITONEI ...
The word ascites is of Greek origin (askos) and means bag or sac. Ascites describes the condition of pathologic fluid collection within the abdominal cavity.
Bedside Intraperitoneal Chemotherapy for Recurrent Pseudomyxoma Peritonei, an Alternative to Current Methods in a Low-Resource ... Pseudomyxoma peritonei (PMP) is a condition presenting with tumors of the abdominal cavity presenting which could lead ... Bedside Intraperitoneal Chemotherapy for Recurrent Pseudomyxoma Peritonei, an Alternative to Current Methods in a Low-Resource ...
Pseudomyxoma Peritonei. *Pseudopolyposis Of Colon. *Pyloroplasty. *Pyogenic Granuloma. *Quadrantectomy. *Radiation Proctitis. * ...
Four cases of pseudomyxoma peritonei with ovarian tumors at our hospital. Riho Yazawa, Hiroyuki Yazawa, Kaoru Fukuda, Miki ...
Pseudomyxoma Peritonei * Radical Hysterectomy * Radical Trachelectomy * Radical Vulvectomy * Recurrent Cervical Cancer * ...
Pseudomyxoma Survivor A registered charity which provides a support network for survivors and carers of Pseudomyxoma Peritonei ... Pseudomyxoma peritonei Cancer Research UK. CancerHelp information is examined by both expert and lay reviewers. Content is ... Pseudomyxoma peritonei Macmillan Cancer Support. Content is developed by a team of information development nurses and content ... Pseudomyxoma peritonei induced by low-grade appendiceal mucinous neoplasm accompanied by rectal cancer: a case report and ...
The pseudomyxoma peritonei occurs as a complication of the following ovarian tumor:. *. A. ... Causes of pseudomyxoma peritonei - Mucinous cystadenoma of ovary, mucocele of appendix, carcinoma of large intestine in men ...
pseudomyxoma peritonei Thu Aug 25, 2005 6:45 am. jgterlouw. 8. phyllodes tumor Texas ...
pseudomyxoma peritonei Thu Aug 25, 2005 6:45 am. jgterlouw. 8. phyllodes tumor Texas ...
Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol. 2008;34:196-201. [PubMed] [DOI] [ ... "pseudomyxoma peritonei". Am J Surg Pathol. 1995;19:1390-1408. [PubMed] [DOI] [Cited in This Article: ] [Cited by in Crossref: ... Nonaka D, Kusamura S, Baratti D, Casali P, Younan R, Deraco M. CDX-2 expression in pseudomyxoma peritonei: a ... Patients with pseudomyxomaperitonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable ...
Mucinous appendiceal neoplasms with or without pseudomyxoma peritonei: a review. Soucisse ML, Lansom J, Alshahrani MS, Morris ...
The larger varieties are associated with an increased risk of rupture, with resultant pseudomyxoma peritonei. ...
Vermiform appendix: acute appendicitis, mucocele, adenoma and adenocarcinoma of the appendix, pseudomyxoma peritonei, ...
http://en.wikipedia.org/wiki/Pseudomyxoma_peritonei We dont know this is what she has for sure. Who knows with those ...
Pseudomyxoma Peritonei After a Total Pancreatectomy for Intraductal Papillary Mucinous Neoplasm With Colloid Carcinoma in Lynch ...
These tumors were examined by a pathologist, who identified the cancer as pseudomyxoma peritonei, a cancer of the appendix. ...
Urachal adenocarcinoma in situ with pseudomyxoma peritonei: a case report (1 February, 2003) Free G Stenhouse, D McRae, A M ...
Doxorubicin Efficacy with Photodynamic Therapy in a Three-Dimensional Model for Micrometastatic Pseudomyxoma Peritonei ...
They are often associated to pseudomyxoma peritonei (PMP) a condition characterized by the presence of mucinous ascites and ... but mostly are associated with pseudomyxoma peritonei and probably all these case can be considered of primary gastrointestinal ...
... and pseudomyxoma peritonei. ...
Appendiceal carcinoma, pseudomyxoma peritonei (PMP)* and other peritoneal surface malignancies are rare and, sadly, all too ...
  • METHODS: In a multi-institutional study prospective databases of patients with peritoneal carcinomatosis (PC) from colorectal cancer and pseudomyxoma peritonei (PMP) treated according to the Dutch HIPEC protocol, a uniform approach for the CRS and HIPEC treatment, were reviewed. (lu.se)
  • Pseudomyxoma peritonei (PMP) is a condition presenting with tumors of the abdominal cavity presenting which could lead abdominal distention and ascites secondary to mucus production. (upr.edu)
  • These tumors were examined by a pathologist, who identified the cancer as pseudomyxoma peritonei, a cancer of the appendix. (findlaw.com)
  • Of the variety of tumors that are treated with this method, probably the most common indication are these low grade appendiceal cancers or what is clinically referred to as pseudomyxoma peritonei, and this is a situation in which patients can develop a significant amount of mucin in their abdomen, produced by the tumor cells that can be very problematic, and that may not necessarily be very responsive to conventional systemic therapies. (reachmd.com)
  • Promoting Awareness of PMP (Pseudomyxoma Peritonei), Appendiceal Cancer and other Peritoneal Surface Malignancies. (cancerindex.org)
  • A charitable organization founded in 2008 by a community of individuals affected by Pseudomyxoma Peritonei (PMP) and related Peritoneal Surface Malignancies (PSM). (cancerindex.org)
  • Appendiceal carcinoma, pseudomyxoma peritonei (PMP)* and other peritoneal surface malignancies are rare and, sadly, all too often misdiagnosed or poorly managed. (tuftsmedicalcenter.org)
  • Pseudomyxoma Survivor is dedicated to supporting those affected by pseudomyxoma peritonei (PMP), appendix cancer and other peritoneal surface malignancies through practical and emotional support. (pseudomyxomasurvivor.org)
  • Pseudomyxoma Peritonei ( PMP ) is a more common name given to the "jelly belly" syndrome caused by mucinous adenoma and mucinous adenocarcinoma. (cancerindex.org)
  • HIPEC is an effective treatment for cancers in the lining of the abdominal cavity ( peritoneal cancer ), including pseudomyxoma peritonei, mucinous adenocarcinoma of the appendix and peritoneal mesothelioma. (ucsd.edu)
  • Pseudomyxoma Survivor is a global charity (non-profit) which supports and advises patients with pseudomyxoma peritonei. (wikipedia.org)
  • Following his nomination for this role by Pseudomyxoma Survivor and subsequent appointment for 2014, Sean will once again shed light on rare diseases such as PMP and appendix cancer which afflicted his mother, Audrey Hepburn, for International Rare Disease Day on February 28, 2015 . (constantcontact.com)
  • The charity is listed by Macmillan Cancer Support as the primary support route for pseudomyxoma peritonei and is also recognised by the UK National Health Service and by Cancer Research UK as a useful source of information and support for their patients. (wikipedia.org)
  • She specialises in the management of colorectal cancer and pseudomyxoma peritonei, performing surgery for these conditions by both open and laparoscopic approaches, including cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC). (christie.nhs.uk)
  • Is pseudomyxoma peritonei a cancer? (pseudomyxomasurvivor.org)
  • Yes, pseudomyxoma peritonei (PMP) is a rare cancer that usually starts in the appendix and can spread to the peritoneum, which is the lining of the abdominal cavity. (pseudomyxomasurvivor.org)
  • The FORMA-05 clinical study was a prospective, randomised, single-blind, controlled, non-inferiority study which compared the efficacy of Octapharma's high-purity human fibrinogen concentrate to that of cryoprecipitate during cytoreductive surgery to treat pseudomyxoma peritonei, a rare cancer that usually starts in the appendix. (octapharma.com)
  • Pseudomyxoma Peritonei (PMP) and Peritoneal Mesothelioma (PM) are both rare peritoneal malignancies. (bvsalud.org)
  • Our Frequently Asked Questions ( FAQ s) for Pseudomyxoma Peritonei (PMP) and Appendix Cancers. (pseudomyxomasurvivor.org)
  • The key prognostic factor for pseudomyxoma peritonei is how completely the cytoreduction surgery removes all visible tumours.What is the most important prognostic factor for pseudomyxoma peritonei? (pseudomyxomasurvivor.org)
  • The larger varieties are associated with an increased risk of rupture, with resultant pseudomyxoma peritonei. (medscape.com)
  • It is registered with the Charity Commission for England and Wales as charity number 1143642 and provides specialist health care information and financial support to people affected by pseudomyxoma peritonei. (wikipedia.org)
  • The patron of the charity is Sean Hepburn-Ferrer, the son of Audrey Hepburn who died of pseudomyxoma peritonei in 1993. (wikipedia.org)
  • A registered charity which provides a support network for survivors and carers of Pseudomyxoma Peritonei. (cancerindex.org)
  • Pseudomyxoma peritonei (PMP) is a rare and intractable disease with an estimated incidence of one per million population per year. (irdrjournal.com)
  • Pseudomyxoma peritonei as an intractable disease and its preoperative assessment to help improve prognosis after surgery: A review of the literature. (irdrjournal.com)
  • Pseudomyxoma peritonei as an intractable disease and its preoperative assessment to help improve pro. (irdrjournal.com)
  • A $50,000, two-year grant has been awarded to Dr. Venkatesh Govindarajan of Creighton University for his project "Targeted Parallel Pathway Blockade as a Treatment Option for Pseudomyxoma Peritonei," which will test the effectiveness of combinatorial targeting of two signaling networks driven by MEK and PI3K in preclinical models of PMP. (constantcontact.com)
  • In 2016 She was awarded the Royal Society of Medicine Normal Tanner Medal for her work on the impact of UK specialist-services commissioning on referral and treatment pathways in pseudomyxoma peritonei. (christie.nhs.uk)
  • Engaging in exercise is generally beneficial for overall health and well-being, even for individuals with pseudomyxoma peritonei (PMP). (pseudomyxomasurvivor.org)
  • For those that are newly diagnosed, there is buddy system, Pseudomyxoma Buddies, which is free of charge and available UK wide. (cancerindex.org)
  • Pseudomyxoma peritonei (PMP) is a rare disease characterized by mucinous ascites and deposits on the peritoneal surfaces. (nih.gov)
  • Pseudomyxoma peritonei (PMP) is a rare condition characterized by intraperitoneal dissemination of mucinous neoplasia affecting about 1 patient per million population per year [ 1 ]. (biomedcentral.com)
  • 4. Mucinous Balls Tangled With Mesothelial Cells and MUC2-Positive Cancer Cells in the Ascites of Pseudomyxoma Peritonei. (nih.gov)
  • 9. Ovarian mucinous tumour arising in mature cystic teratoma and associated with pseudomyxoma peritonei: report of two cases and comparison with ovarian involvement by low-grade appendiceal mucinous tumour. (nih.gov)
  • 10. Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei. (nih.gov)
  • 12. Ovarian mucinous tumor arising in mature cystic teratoma associated with pseudomyxoma peritonei: a case with possible respiratory epithelial differentiation. (nih.gov)
  • 14. Mucinous ovarian tumors associated with pseudomyxoma peritonei of adenomucinosis type: immunohistochemical evidence that they are secondary tumors. (nih.gov)
  • 15. "Pseudomyxoma Endometrii": Endometrial Deposition of Acellular Mucin from a Low-Grade Appendiceal Mucinous Neoplasm as a Rare Mimic of Myxoid Uterine Tumors. (nih.gov)
  • 17. Pseudomyxoma peritonei in women: a clinicopathologic analysis of 30 cases with emphasis on site of origin, prognosis, and relationship to ovarian mucinous tumors of low malignant potential. (nih.gov)
  • 18. Mucinous tumors arising in ovarian mature cystic teratomas: relationship to the clinical syndrome of pseudomyxoma peritonei. (nih.gov)
  • We describe four cases of pseudomyxoma peritonei (PMP) that were diagnosed and treated at our hospital.Case 1: A 26-year-old woman with a large multicystic ovarian tumor and massive ascites was diagnosed with PMP originating from a borderline mucinous ovarian tumor. (bvsalud.org)
  • The Foundation was created in 2008 by a community of individuals affected by Pseudomyxoma Peritonei (PMP), Appendix Cancer, and related Peritoneal Surface Malignancies (PSM). (rarediseases.org)
  • ACPMP is dedicated to (1) funding and supporting research to find a cure for Pseudomyxoma Peritonei (PMP), Appendix Cancer, and related Peritoneal Surface Malignancies (PSM), and (2) funding educational programs to educate physicians and patients about these diseases. (rarediseases.org)
  • Following the diagnosis of an extremely rare form of appendix cancer called pseudomyxoma peritonei (PMP) and the failure of conventional treatments that included surgery and chemotherapy, Andy was told he had six months to live. (clevelandclinic.org)
  • Andreana Holowatyj, PhD, MSCI, assistant professor of Medicine and Cancer Biology, has been named the inaugural chair of the scientific advisory board for the Appendix Cancer Pseudomyxoma Peritonei Research Foundation. (vumc.org)
  • Complete cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is the only curative treatment for pseudomyxoma peritonei (PMP) arising from the appendix. (biomedcentral.com)
  • RESULTS: There is still controversy regarding the best treatment strategy for patients with recurrent pseudomyxoma peritonei (PMP) after CRS and HIPEC. (bvsalud.org)
  • 5. Pseudomyxoma peritonei and selected other aspects of the spread of appendiceal neoplasms. (nih.gov)
  • Mitomycin-C is used for the diseases of the gastrointestinal tract (pseudomyxoma peritonei, colorectal cancer, gastric cancer, appendiceal cancer, and cancer of the small bowel), for 90 minutes at 42-430C. (apostolos-tentes.com)
  • The majority of patients with pseudomyxoma peritonei of appendiceal origin who have complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy are cured. (eu.com)
  • Pseudomyxoma peritonei (PMP) is an extremely rare malignancy, characterized by extensive peritoneal implantation and colloidal ascites. (nih.gov)
  • BACKGROUND: Pseudomyxoma peritonei syndrome (PMP) is an orphan disease. (bvsalud.org)
  • 13. CDX-2 expression in pseudomyxoma peritonei: a clinicopathological study of 42 cases. (nih.gov)
  • Adenocarcinoma peritoneal caracterizado por acumulación de MOCO en la CAVIDAD PERITONEAL. (bvsalud.org)
  • An extraperitoneal surgical preparation technique leads to effective en bloc resection of the peritoneum and the affected abdominal area. (bvsalud.org)
  • The post-operative outcome was good without metastasis, recurrence, and pseudomyxoma peritonei. (gastrores.org)
  • The charity is listed by Macmillan Cancer Support as the primary support route for pseudomyxoma peritonei and is also recognised by the UK National Health Service and by Cancer Research UK as a useful source of information and support for their patients. (wikipedia.org)
  • Find out what dietary advice to follow if you're a pseudomyxoma peritonei cancer patient at The Christie and your bowel habit has changed. (christie.nhs.uk)
  • Pseudomyxoma Survivor is a global charity (non-profit) which supports and advises patients with pseudomyxoma peritonei. (wikipedia.org)
  • 8. MUC2, MUC5AC and MUC5B in the mucus of a patient with pseudomyxoma peritonei: biochemical and immunohistochemical study. (nih.gov)